References
- Siegel RL, Miller KD and Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30. DOI: 10.3322/caac.21442
- Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S and Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016; 4(3): 118–124. DOI: 10.1016/j.prnil.2016.07.001
- Bashir MN. Epidemiology of Prostate Cancer. Asian Pac J Cancer Prev. 2015; 16(13): 5137–5141. DOI: 10.7314/APJCP.2015.16.13.5137
- Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012; 30(2): 195–200. DOI: 10.1007/s00345-012-0824-2
- McDavid K, Lee J, Fulton JP, Tonita J and Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 2004; 119(2): 174–186. DOI: 10.1177/003335490411900211
- Kelly SP, Rosenberg PS, Anderson WF, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol. 2017; 71(2): 195–201. DOI: 10.1016/j.eururo.2016.05.011
- Zhang K, Bangma CH and Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol. 2017; 4(2): 86–95. DOI: 10.1016/j.ajur.2016.08.010
- Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer. 2016; 138(6): 1388–1400. DOI: 10.1002/ijc.29894
- Carducci MA, Cetin K, Markus R and Fryzek JP. Time trends in the epidemiology of newly diagnosed stage IV prostate cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988–2003). Journal of Clinical Oncology. 2008; 26(15_suppl): 5059. DOI: 10.1200/jco.2008.26.15_suppl.5059
- Salehiniya H, Pakzad R, Hassanipour S and Mohammadian M. The incidence and mortality of thyroid cancer and its relationship with HDI in the world. World Cancer Research Journal. 2018; 5(2): 1–6.
- Chornokur G, Dalton K, Borysova ME and Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011; 71(9): 985–997. DOI: 10.1002/pros.21314
- Hajjar RR, Atli T, Al-Mandhari Z, Oudrhiri M, Balducci L and Silbermann M. Prevalence of aging population in the Middle East and its implications on cancer incidence and care. Ann Oncol. 2013; 24(Suppl 7): vii11–24. DOI: 10.1093/annonc/mdt268
- Gu X, Zheng R, Xia C, et al. Interactions between life expectancy and the incidence and mortality rates of cancer in China: A population-based cluster analysis. Cancer Commun (Lond). 2018; 38(1): 44. DOI: 10.1186/s40880-018-0308-x
- Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I and Salehiniya H. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015; 3(4): 135–140. DOI: 10.1016/j.prnil.2015.09.001
- Baade PD, Youlden DR, Cramb SM, Dunn J and Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate International. 2013; 1(2): 47–58. DOI: 10.12954/PI.12014
- Cullen J, Elsamanoudi S, Brassell SA, et al. The burden of prostate cancer in Asian nations. J Carcinog. 2012; 11: 7. DOI: 10.4103/1477-3163.94025
- Chen SL, Wang SC, Ho CJ, et al. Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. Sci Rep. 2017; 7:
40003 . DOI: 10.1038/srep40003 - Chen JG, Zhu J, Zhang YH and Lu JH. Cancer survival in Qidong, China, 1992–2000. IARC Sci Publ. 2011; 162: 43–53.
- Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH and Lee JS. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014; 46(2): 109–123. DOI: 10.4143/crt.2014.46.2.109
- Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011; 43(1): 1–11. DOI: 10.4143/crt.2011.43.1.1
- Jung KW, Won YJ, Oh CM, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014. Cancer Res Treat. 2017; 49(2): 292–305. DOI: 10.4143/crt.2017.118
- Zahir ST, Nazemian MR, Zand S and Zare S. Survival of patients with prostate cancer in Yazd, Iran. Asian Pac J Cancer Prev. 2014; 15(2): 883–886. DOI: 10.7314/APJCP.2014.15.2.883
- Wang F, Feng J, Chen P, et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clinics and Research in Hepatology and Gastroenterology. 2017; 41(4): 466–475. DOI: 10.1016/j.clinre.2017.04.004
- Xu H, Zhang LM, Liu J, Ding GX, Ding Q and Jiang HW. The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: A prospective cohort study. J Cancer Res Clin Oncol. 2013; 139(6): 943–951. DOI: 10.1007/s00432-013-1407-3
- Kelloff GJ, Choyke P and Coffey DS. Prostate Cancer Imaging Working G. Challenges in clinical prostate cancer: Role of imaging. AJR Am J Roentgenol. 2009; 192(6): 1455–1470. DOI: 10.2214/AJR.09.2579
- Myint Z, Huang B, Chen Q and Wang P. Epidemiology and survival disparities of prostate cancer in Appalachian Kentucky. Journal of Clinical Oncology. 2018; 36(6_suppl): 292–292. DOI: 10.1200/JCO.2018.36.6_suppl.292
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1): 1. DOI: 10.1186/2046-4053-4-1
- Penson DF, Krishnaswami S, Jules A, Seroogy JC and McPheeters ML. Evaluation and treatment of cryptorchidism. 2012.
- Human Development Reports. 2018.
http://hdr.undp.org/en/2018-update . - Jung KW, Yim SH, Kong HJ, et al. Cancer survival in Korea 1993–2002: A population-based study. J Korean Med Sci. 2007; 22(Suppl): S5–S10. DOI: 10.3346/jkms.2007.22.S.S5
- Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012; 44(1): 11–24. DOI: 10.4143/crt.2012.44.1.11
- Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG and Lee JS. Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013; 45(1): 1–14. DOI: 10.4143/crt.2013.45.1.1
- Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47(2): 127–141. DOI: 10.4143/crt.2015.060
- Oh CM, Won YJ, Jung KW, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016; 48(2): 436–450. DOI: 10.4143/crt.2016.089
- Jung KW, Won YJ, Kong HJ, Lee ES and Community of Population-Based Regional Cancer R. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018; 50(2): 303–316. DOI: 10.4143/crt.2018.143
- Jin F, Xiang YB and Gao YT. Cancer survival in Shanghai, People’s Republic of China. IARC Sci Publ. 1998; 145: 37–50.
- Xishan H, Chen K, Min H, Shufen D and Jifang W. Cancer survival in Tianjin, China, 1991–1999. IARC Sci Publ. 2011; 162: 69–84.
- Chen JG, Chen HZ, Zhu J, et al. Cancer survival in patients from a hospital-based cancer registry, China. J Cancer. 2018; 9(5): 851–860. DOI: 10.7150/jca.23039
- Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018; 6(5): e555–e567. DOI: 10.1016/S2214-109X(18)30127-X
- Sato Y. Survival Trends of Patients Treated at the National Cancer Center Hospital, Japan, from 1962 to 1994. Japanese Journal of Clinical Oncology. 2002; 32(5): 181–186. DOI: 10.1093/jjco/hyf037
- Tsukuma H, Ajiki W, Ioka A, Oshima A and Research Group of Population-Based Cancer Registries of J. Survival of cancer patients diagnosed between 1993 and 1996: A collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol. 2006; 36(9): 602–607. DOI: 10.1093/jjco/hyl068
- Matsuda T, Ajiki W, Marugame T, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: A chronological and international comparative study. Jpn J Clin Oncol. 2011; 41(1): 40–51. DOI: 10.1093/jjco/hyq167
- Ito Y, Nakayama T, Miyashiro I, Ioka A and Tsukuma H. Conditional survival for longer-term survivors from 2000–2004 using population-based cancer registry data in Osaka, Japan. BMC Cancer. 2013; 13: 304. DOI: 10.1186/1471-2407-13-304
- Ito Y, Miyashiro I, Ito H, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014; 105(11): 1480–1486. DOI: 10.1111/cas.12525
- Jayalekshmi P, Gangadharan P and Sebastian P. Cancer survival in Karunagappally, India, 1991–1997. IARC Sci Publ. 2011; 162: 125–132.
- Yeole BB, Kurkure AP and Sunny L. Cancer survival in Mumbai (Bombay), India, 1992–1999. IARC Sci Publ. 2011; 162: 133–142.
- Balasubramaniam G, Talole S, Mahantshetty U, Saoba S and Shrivastava S. Prostate cancer: a hospital-based survival study from Mumbai, India. Asian Pac J Cancer Prev. 2013; 14(4): 2595–2598. DOI: 10.7314/APJCP.2013.14.4.2595
- Takiar R, Krishnan SK and Shah VP. A model approach to calculate cancer prevalence from 5 years survival data for selected cancer sites in India—Part II. Asian Pac J Cancer Prev. 2014; 15(14): 5681–5684. DOI: 10.7314/APJCP.2014.15.14.5681
- Martin N, Srisukho S, Kunpradist O and Suttajit M. Cancer survival in Chiang Mai, Thailand. IARC Sci Publ. 1998; 145: 109–121.
- Martin N, Pongnikorn S, Patel N and Daoprasert K. Cancer survival in Lampang, Thailand, 1990–2000. IARC Sci Publ. 2011; 162: 217–226.
- Sriplung H and Prechavittayakul P. Cancer survival in Songkhla, Thailand, 1990–1999. IARC Sci Publ. 2011; 162: 227–235.
- Sumitsawan Y, Srisukho S, Sastraruji A, Chaisaengkhum U, Maneesai P and Waisri N. Cancer survival in Chiang Mai, Thailand, 1993–1997. IARC Sci Publ. 2011; 162: 199–209.
- Lim GH, Wong CS, Chow KY, Bhalla V and Chia KS. Trends in long-term cancer survival in Singapore: 1968–2002. Ann Acad Med Singapore. 2009; 38(2): 99–105.
- Chia KS. Cancer survival in Singapore, 1993–1997. IARC Sci Publ. 2011; 162: 183–198.
- Chang CM, Huang KY, Hsu TW, et al. Multivariate analyses to assess the effects of surgeon and hospital volume on cancer survival rates: A nationwide population-based study in Taiwan. PLoS One. 2012; 7(7):
e40590 . DOI: 10.1371/journal.pone.0040590 - Chien LH, Tseng TJ, Tsai FY, et al. Patterns of age-specific socioeconomic inequalities in net survival for common cancers in Taiwan, a country with universal health coverage. Cancer Epidemiol. 2018; 53: 42–48. DOI: 10.1016/j.canep.2018.01.006
- Law SC and Mang OW. Cancer survival in Hong Kong SAR, China, 1996–2001. IARC Sci Publ. 2011; 162: 33–41.
- Esteban D, Ngelangel C, Lacaya L, Robles E and Monson M. Cancer survival in Rizal, Philippines. IARC Sci Publ. 1998; 145: 101–108.
- Chia SE, Tan CS, Lim GH, Sim X, Lau W and Chia KS. Incidence, mortality and five-year relative survival ratio of prostate cancer among Chinese residents in Singapore from 1968 to 2002 by metastatic staging. Annals Academy of Medicine Singapore. 2010; 39(6): 466–471.
- Sankaranarayanan R, Swaminathan R, Jayant K and Brenner H. An overview of cancer survival in Africa, Asia, the Caribbean and Central America: The case for investment in cancer health services. IARC Sci Publ. 2011; 162: 257–291.
- Maringe C, Li R, Mangtani P, Coleman MP and Rachet B. Cancer survival differences between South Asians and non-South Asians of England in 1986–2004, accounting for age at diagnosis and deprivation. Br J Cancer. 2015; 113(1): 173–181. DOI: 10.1038/bjc.2015.182
- Taitt HE. Global trends and prostate cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018; 12(6): 1807–1823. DOI: 10.1177/1557988318798279
- Kimura T. East meets West: Ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012; 31(9): 421–429. DOI: 10.5732/cjc.011.10324
- Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15(11): e484–492. DOI: 10.1016/S1470-2045(14)70211-6
- Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9(8): 730–756. DOI: 10.1016/S1470-2045(08)70179-7
- Bekelman JE, Rumble RB, Chen RC, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018; 36(32):
JCO1800606 . DOI: 10.1200/JCO.18.00606 - Steele CB, Li J, Huang B and Weir HK. Prostate cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer. 2017; 123(Suppl 24): 5160–5177. DOI: 10.1002/cncr.31026
- Critz FA, Benton JB, Shrake P and Merlin ML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol. 2013; 189(3): 878–883. DOI: 10.1016/j.juro.2012.10.061